Purpose | Board Meetings Date | Announcement Date |
---|---|---|
Board Meeting | 7 May 2024 | 22 Mar 2024 |
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ending on March 31 2024 and to recommend dividend If any for the financial year 2023-24. Audited Financial results for the quarter and year ended March 31, 2024 Outcome of Board Meeting - Audited Financial Results for the quarter and year ended March 31, 2024 Dividend updates Change in Key Managerial Personnel 40th Annual General Meeting (AGM) of the Company is scheduled to be held on Monday, July 29, 2024 The Register of members and the Share Transfer books of the Company shall remain closed from Wednesday, July 17, 2024 to Friday, July 19, 2024 (both days inclusive) for the purpose of the Dividend and Annual General Meeting of the Company (As Per BSE Announcement Dated on 07.05.2024) | ||
Board Meeting | 30 Jan 2024 | 21 Dec 2023 |
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 inter alia to consider and approve The unaudited financial results for the Company for the quarter and nine months ending December 31 2023 Outcome of Board meeting - Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2023. Announcement under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Unaudited Financial results for the Quarter and Nine Months ended December 31, 2023 (As Per BSE Announcement Dated on 30/01/2024) | ||
Board Meeting | 27 Oct 2023 | 22 Sep 2023 |
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter and half year ending on September 30 2023. Outcome of Board Meeting - Unaudited Financial Results for the quarter and half-year ended September 30, 2023 Unaudited Financial results for the quarter and half-year ended September 30, 2023 (As per BSE Announcement Dated on 27/10/2023) | ||
Board Meeting | 28 Sep 2023 | 14 Mar 2024 |
Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 | ||
Board Meeting | 26 Jul 2023 | 21 Jun 2023 |
DR.REDDYs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2023 inter alia to consider and approve Consideration and approval of the Unaudited Financial Results of the Company for the quarter ending on June 30 2023. Outcome of Board Meeting - Unaudited Financial Results for the quarter ended June 30, 2023 Announcement under Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (SEBI Listing Regulations) Unaudited Financial results for quarter ended June 30, 2023 Retirement of Mr. Sridar Iyengar (DIN:00278512), Independent Director of the Company (As Per BSE Announcement dated on 26.07.2023) |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.